Literature DB >> 15390131

Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration.

Emma C Schofield1, Diana Caine, Jillian J Kril, Nicholas J Cordato, Glenda M Halliday.   

Abstract

The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005-1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (chi(2) = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. (c) 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15390131     DOI: 10.1002/mds.20286

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Pathological staging of frontotemporal lobar degeneration.

Authors:  Jillian J Kril; Glenda M Halliday
Journal:  J Mol Neurosci       Date:  2011-05-07       Impact factor: 3.444

Review 3.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

4.  Rates of cerebral atrophy differ in different degenerative pathologies.

Authors:  Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs
Journal:  Brain       Date:  2007-03-08       Impact factor: 13.501

5.  Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis.

Authors:  Fang Yu; Daniel S Barron; Bundhit Tantiwongkosi; Peter Fox
Journal:  Brain Behav       Date:  2015-03-11       Impact factor: 2.708

6.  18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Authors:  Luca Passamonti; Patricia Vázquez Rodríguez; Young T Hong; Kieren S J Allinson; David Williamson; Robin J Borchert; Saber Sami; Thomas E Cope; W Richard Bevan-Jones; P Simon Jones; Robert Arnold; Ajenthan Surendranathan; Elijah Mak; Li Su; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

Review 7.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

Review 8.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.